Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) – National Quality Strategy
Domain: Communication and Care Coordination

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
CLAIMS, REGISTRY

DESCRIPTION:
Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as NSCLC-NOS with an explanation included in the pathology report.

INSTRUCTIONS:
This measure is to be reported each time a patient’s pathology report addresses specimens with a diagnosis of non-small cell lung cancer; however, only one QDC per date of service for a patient is required. This measure may be reported by eligible professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Reporting via Claims:
ICD-10-CM diagnosis codes, CPT codes, and patient demographics are used to identify patients who are included in the measure’s denominator. Quality-data codes are used to report the numerator of the measure.

When reporting the measure via claims, submit the listed ICD-10-CM diagnosis codes, and CPT codes, and the appropriate quality-data code.

Measure Reporting via Registry:
ICD-10-CM diagnosis codes, CPT codes, and patient demographics are used to identify patients who are included in the measure’s denominator. The numerator options as described in the quality-data codes are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
Biopsy and cytology specimen reports with a diagnosis of primary non-small cell lung cancer

Denominator Criteria (Eligible Cases):
Patients ≥ 18 years of age on date of encounter
AND
Diagnosis for lung cancer (ICD-10-CM): C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
AND
Patient encounter during reporting period (CPT): 88104, 88108, 88112, 88173, 88305

NUMERATOR:
Biopsy and cytology specimen reports with a diagnosis of primary non-small cell lung cancer classified into specific histologic type (squamous cell carcinoma, adenocarcinoma) OR classified as NSCLC-NOS with an explanation included in the pathology report

Numerator Quality-Data Coding Options for Reporting Satisfactorily:
Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Classified
Performance Met: G9418: Primary non-small cell lung cancer biopsy and cytology specimen report documents classification into specific
histologic type OR classified as NSCLC-NOS with an explanation

OR

Non-small cell lung Cancer Biopsy and Cytology Specimen Reports not Classified for a Medical Reason

Medical Performance Exclusion: G9419:
Documentation of medical reason(s) for not including the histological type OR NSCLC-NOS classification with an explanation (e.g., biopsy taken for other purposes in a patient with a history of primary non-small cell lung cancer or other documented medical reasons)

OR

If patient is not eligible for this measure because the specimen is not of lung origin or is not classified as non-small cell lung cancer report:

Other Performance Exclusion: G9420:
Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer

OR

Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports not Classified, Reason not given

Performance Not Met: G9421:
Primary non-small cell lung cancer biopsy and cytology specimen report does not document classification into specific histologic type OR classified as NSCLC-NOS with an explanation

RATIONALE:
Lung cancer is the most frequent cause of major cancer incidence and mortality worldwide. The classifications of lung cancer published by the World Health Organization (WHO) in 1967, 1981, and 1999 were written primarily by pathologists for pathologists. Only in the 2004 revision, relevant genetics and clinical information were introduced. Nevertheless, because of remarkable advances over the last 6 years in our understanding of lung adenocarcinoma, particularly in area of medical oncology, molecular biology, and radiology, there is a pressing need for a revised classification, based not on pathology alone, but rather on an integrated multidisciplinary platform.

For the first time, this classification addresses an approach to small biopsies and cytology in lung cancer diagnosis. Recent data regarding EGFR mutation predicting responsiveness to EGFR-TKIs, toxicities, and therapeutic efficacy have established the importance of distinguishing squamous cell carcinoma from adenocarcinoma and non-small cell lung carcinoma (NSCLC) not otherwise specified (NOS) in patients with advanced lung cancer. Approximately 70% of lung cancers are diagnosed and staged by small biopsies or cytology rather than surgical resection specimens, with increasing use of transbronchial needle aspiration (TBNA), endobronchial ultrasound-guided TBNA and esophageal ultrasound-guided needle aspiration. Within the NSCLC group, most pathologists can identify well- or moderately-differentiated squamous cell carcinomas or adenocarcinomas, but specific diagnoses are more difficult with poorly differentiated tumors. Nevertheless, in small biopsies and/or cytology specimens, 10 to 30% of specimens continue to be diagnosed as NSCLC-NOS.

CLINICAL RECOMMENDATION STATEMENTS:
To address advances in oncology, molecular biology, pathology, radiology, and surgery of lung adenocarcinoma, an international multidisciplinary classification was sponsored by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society. This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small non-resection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
For small biopsies and cytology, we recommend that NSCLC be further classified into a more specific histologic type, such as adenocarcinoma or squamous cell carcinoma, whenever possible (strong recommendation, moderate quality evidence).

We recommend that the term NSCLC-NOS be used as little as possible and we recommend it be applied only when a more specific diagnosis is not possible by morphology and/or special stains (strong recommendation, moderate quality evidence).

The above strategy for classification of adenocarcinoma versus other histologies and the terminology should be used in routine diagnosis and future research and clinical trials so that there is uniform classification of disease cohorts in relationship to tumor subtypes.


COPYRIGHT:
Physician Performance Measures (Measures) and related data specifications developed by the College of American Pathologists are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. They are designed for use by any physician who manages the care of a patient for a specific condition or for diagnosis or prevention. These Measures are not clinical guidelines and do not establish a standard of medical care. The College has not tested its Measures for all potential applications.

Measures are subject to review and may be revised or rescinded at any time by the College. They may not be altered without the prior written approval of the College of American Pathologists. Measures developed by the College of American Pathologists, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use of the Measures is not permitted absent a license agreement between the user and the College of American Pathologists. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. The College of American Pathologists is not responsible for any harm to any party resulting from the use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
© 2012 College of American Pathologists. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The College of American Pathologists disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.
© 2007 and © 2012, College of American Pathologists. All rights reserved

2016 Claims Individual Measure Flow
PQRS #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

Start

Denominator

Patient Age at Date of Service ≥ 18 years

Not Included in Eligible Population/Denominator

Diagnosis of Lung Cancer as Listed in Denominator*

No

Yes

No

Yes

Encounter as Listed in Denominator* (1/1/2016 thru 12/31/2016)

Include in Eligible Population/Denominator (8 procedures)

Numerator

Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation

Yes

No

Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation

Reporting Met + Performance Exclusion G9419 (1 procedure)
b

Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer

No

Yes

Reporting Met + Performance Exclusion G9421 (9 procedures)
b

Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given

No

Yes

Reporting Met + Performance Not Met G9420 (2 procedures)
c


SAMPLE CALCULATIONS:

Reporting Rate:
Performance Met (a=4 procedures) + Performance Exclusion (b=1 procedure) + Performance Not Met (c=2 procedures) = 7 procedures = 87.50%
Eligible Population/Denominator (d=8 procedures)

Performance Rate:
Reporting Numerator (7 procedures) – Performance Exclusion (b=1 procedure) + Performance Not Met (c=2 procedures) = 66.67%

*See the posted Measure Specification for specific coding and instructions to report this measure.
NOTE: Reporting Frequency: Procedure

CPT only copyright 2015 American Medical Association. All rights reserved.
11/17/2015 Page 4 of 9
2016 Registry Individual Measure Flow
PQRS #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

SAMPLE CALCULATIONS:

Reporting Rate=
Performance Met (a=4 procedures) + Performance Exclusion (b=1 procedure) + Performance Not Met (c=2 procedures) = 7 procedures/8 procedures = 87.50%

Performance Rate=
Performance Met (a=4 procedures) = 4 procedures/8 procedures = 66.67%
Reporting Numerator (7 procedures) - Performance Exclusion (b=1 procedure) = 6 procedures

*See the posted Measure Specification for specific coding and instructions to report this measure.
NOTE: Reporting Frequency/Procedure
2016 Claims Individual Measure Flow
PQRS #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patient Age:
   a. If the Age is greater than or equal to 18 years of age at Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If the Age is greater than or equal to 18 years of age at Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Lung Cancer as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of Lung Cancer as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible population.

5. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 procedures in the sample calculation.

6. Start Numerator

7. Check Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation:
   a. If Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation equals Yes, include in Reporting Met and Performance Met.
   b. Reporting Met and Performance Met letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 procedures in Sample Calculation.
   c. If Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation equals No, proceed to check Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation.
8. Check Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation:
   a. If Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation equals Yes, include in the Reporting Met and Performance Exclusion.
   b. Reporting Met and Performance Exclusion letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter b1 equals 1 procedure in the Sample Calculation.
   c. If Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation equals No, proceed to check Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer.

9. Check Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer:
   a. If Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer equals Yes, include in the Reporting Met and Performance Exclusion.
   b. Reporting Met and Performance Exclusion letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter b2 equals 0 procedures in the Sample Calculation.
   c. If Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer equals No, proceed to check Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given.

10. Check Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given:
    a. If Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given equals Yes, include in Reporting Met and Performance Not Met.
    b. Reporting Met and Performance Not Met letter is represented in the Reporting Rate in the Sample Calculation listed at the end of this document. Letter c equals 2 procedures in the Sample Calculation.
    c. If Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given equals No, proceed to Reporting Not Met.

11. Check Reporting Not Met:
    a. If Reporting Not Met, the Quality Data Code or equivalent was not reported. 1 procedure has been subtracted from the reporting numerator in sample calculation.

---

**SAMPLE CALCULATIONS:**

<table>
<thead>
<tr>
<th>Reporting Rate</th>
<th>Performance Met (a=4 procedures) + Performance Exclusion (b1+b2=1 procedure) + Performance Not Met (c=2 procedures) = 7 procedures = 87.50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Population/Denominator (d=6 procedures)</td>
<td></td>
</tr>
<tr>
<td>Performance Rate</td>
<td>Performance Met (a=4 procedures) = 4 procedures = 66.67%</td>
</tr>
<tr>
<td>Reporting Numerator (7 procedures) – Performance Exclusion (b1+b2=1 procedure) = 6 procedures</td>
<td></td>
</tr>
</tbody>
</table>
2016 Registry Individual Measure Flow
PQRS #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator
2. Check Patient Age:
   a. If the Age is greater than or equal to 18 years of age at Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If the Age is greater than or equal to 18 years of age at Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.
3. Check Patient Diagnosis:
   a. If Diagnosis of Lung Cancer as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of Lung Cancer as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible population.
5. Check Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer or G9420:
   a. If Specimen is Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer or G9420 equals Yes, do not include in Eligible Patient Population. Stop Processing.
   b. If Specimen in Not of Lung Origin or is Not Classified as Non-Small Cell Lung Cancer or G9420 equals No, include in the Eligible population.
6. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 procedures in the sample calculation.
7. Start Numerator
8. Check Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation:
   a. If Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation equals Yes, include in Reporting Met and Performance Met.
b. Reporting Met and Performance Met letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 procedures in Sample Calculation.

c. If Primary Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Report Documents Classification into Specific Histologic Type or Classified as NSCLC-NOS with an Explanation equals No, proceed to check Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation.

9. Check Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation:

a. If Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation equals Yes, include in the Reporting Met and Performance Exclusion.

b. Reporting Met and Performance Exclusion letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 1 procedure in the Sample Calculation.

c. If Documentation of Medical Reason(s) for Not Including the Histological Type OR NSCLC-NOS Classification with an Explanation equals No, proceed to check Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given.

10. Check Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given:

a. If Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not given equals Yes, include in Reporting Met and Performance Not Met.

b. Reporting Met and Performance Not Met letter is represented in the Reporting Rate in the Sample Calculation listed at the end of this document. Letter c equals 2 procedures in the Sample Calculation.

c. If Non-Small Cell Lung Cancer Biopsy and Cytology Specimen Reports Not Classified, Reason Not Given equals No, proceed to Reporting Not Met.

11. Check Reporting Not Met:

a. If Reporting Not Met, the Quality Data Code or equivalent was not reported. 1 procedure has been subtracted from the reporting numerator in sample calculation.

<table>
<thead>
<tr>
<th>Sample Calculations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reporting Rate=</td>
</tr>
<tr>
<td>Performance Met (a=4 procedures) + Performance Exclusion (b=1 procedure) + Performance Not Met (c=2 procedures) + Eligible Population/Denominator (d=8 procedures) =</td>
</tr>
<tr>
<td>7 procedures = 87.50%</td>
</tr>
<tr>
<td>Performance Rate=</td>
</tr>
<tr>
<td>Performance Met (a=4 procedures) / Eligible Population/Denominator (d=8 procedures) =</td>
</tr>
<tr>
<td>4 procedures = 66.67%</td>
</tr>
<tr>
<td>Reporting Numerator (7 procedures) - Performance Exclusion (b=1 procedure) / 6 procedures</td>
</tr>
</tbody>
</table>